Conversion of convertible loan notes
Convertible loan notes automatically converted into 95,000 ordinary shares.
- CLN Shares issued 95,000
- Enlarged issued share capital 3,699,539 ordinary shares
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that, further to its announcement on 19 February 2025, the convertible loan notes ("CLNs") automatically converted on 8 March 2025 into 95,000 ordinary shares ("CLN Shares").
An application has been made to the Main Market of the London Stock Exchange, and admission of the CLN Shares to trading is expected on 14 March 2025 ("Admission"). The CLN Shares will rank pari passu with the Company's existing Ordinary Shares.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 3,699,539 ordinary shares. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.